Join
Live feed
·
PRReleasevia Quantisnow
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

ByQuantisnow·Wall Street's wire, on your screen.
PMN· ProMIS Neurosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PMN (ProMIS Neurosciences Inc.) and more on Quantisnow.